Clinical Trial Update: Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of Doxil plus Melphalan plus Velcade (DMV) in relapsed/refractory multiple myeloma; trial terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Melphalan (Melphalan)
• Velcade (bortezomib)

Snippet

Sponsor: University of California, San Francisco | Conditions: Multiple Myeloma, Patient Participation | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-06-17